NCT07090499 2026-03-19A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid TumorsPfizerPhase 1 Recruiting310 enrolled
NCT04485013 2026-02-18TTX-080 HLA-G Antagonist in Subjects With Advanced CancersTizona Therapeutics, IncPhase 1 Recruiting240 enrolled
NCT03993873 2025-10-01SHIELD-1Turning Point Therapeutics, Inc.Phase 1 Active not recruiting95 enrolled
NCT04682431 2024-03-22A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid TumorsIkena OncologyPhase 1 Terminated127 enrolled
NCT04691375 2024-03-22A Study of PY314 in Subjects With Advanced Solid TumorsIkena OncologyPhase 1 Terminated86 enrolled
NCT02900664 2022-03-29A Study of PDR001 in Combination With CJM112, EGF816, IlarisĀ® (Canakinumab) or MekinistĀ® (Trametinib)NovartisPhase 1 Completed283 enrolled
NCT00101972 2022-02-22RAV12 in Treating Patients With Metastatic or Recurrent AdenocarcinomaMacroGenicsPhase 1 Completed53 enrolled